- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 -
Related Questions
How might the reverse stock split influence institutional interest and potential future financing options?
Will the reverse stock split alter the eligibility of Vaxart for any index inclusion or exchange listing requirements?
How does this reverse stock split compare to similar actions taken by peer companies in the biotech sector?
How will the reverse stock split impact the company's market capitalization and float?
What is the expected effect of the reverse stock split on Vaxart's share price and liquidity?
What is the likelihood that the reverse stock split proposal will be approved by shareholders?
What are the potential tax implications for existing shareholders resulting from the reverse stock split?
How could the reverse stock split affect the perception of Vaxart among retail investors and its overall demand?